Publications

* is corresponding author status

2025

  1. Shilpakar R, Shkabari B, Acharya B, Lamichhane N, Paudel BD, Yadav M, Sah GS, Poudyal BS, Gyawali B*. Availability, Affordability, and Variations in Price of GI Cancer Medicines in Nepal. JCO Glob Oncol. 2025 Nov. PMID: 41232056
  2. Stevens SX, Teuwen LA, Gyawali B*. Overall survival assessment in cancer drug trials: a luxury or a necessity? The Lancet Oncol. 2025 Oct. PMID: 41110458.
  3. Datta S, Sharma V, Mukherjee A, Agrawal S, Sirohi B, Gyawali B*. Qualitative study of oncologists’ perceptions on the US Food and Drug Administration approval status and clinical practice guidelines and their impact on local practice patterns in India. BMJ Oncol. 2025 Oct. PMID: 41140437.
  4. Hammond A, Ranganathan S, Jain U, Jain B, Iyengar P, Jay G Feliciano E, Swami N, Wu JF, Gyawali B, Mathew A, Pramesh C, Dee CE, Bray F, & Sengar M. Hematologic cancers in the saarc region: current burden in 2022 and projections to 2050. Blood Global Hematology. 2025 Oct.
  5. Abdihamid O, Gyawali B, Booth CM, Eisenhauer EA, Hopman WM, Shkabari B, Trapani D, Verduzco-Aguirre HC, Wilson BE, Tannock FI*. Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology. European Journal of Cancer. 2025 Oct. PMID: 41046634.
  6. Gyawali B*. Cost of Convenience in Cancer Care. JCO Oncol Pract. 2025 Sep. PMID: 40939137.
  7. Tannock IF*, Pe ML, Booth CM, Brundage M, Cherny NI, Coens C, Eisenhauer EA, Geissler J, Giesinger JM, Gyawali B, Oosting SF, Pond GR, Reijneveld JC, Soto-Perez-de-Celis E, Tregear M, van der Graaf WTA. Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer. Lancet Oncol. 2025 Sep. PMID: 40907528.
  8. Teuwen LA, Pond GR, Gyawali B*. Success in oncology phase 3 trials: a small P value or patient value. J Natl Cancer Inst. 2025 Sep. PMID: 40920131.
  9. Teuwen LA, Gyawali B*. Inferior control arms in oncology trials in LMICs: contextualised or compromised?. BMJ Oncol. 2025 Aug. PMID: 40909186.
  10. Stevens SX* & Gyawali B. CodeBreaK or code blue? Assessing sotorasib’s vital signs in metastatic colorectal cancer. Cancer. 2025 Aug. PMID: 40831024
  11. Gyawali B*, Chen N, Tu D, & Pater J. Financial difficulty among patients with cancer participating in clinical trials and its association with patient survival and quality of life. J Natl Cancer Inst. 2025 Aug. PMID: 40811149
  12. Sherry AD, Miller AM, Parlapalli JP, Kupferman GS, Beck EJ, McDonald J, Kouzy R, Jaoude JA, Lin TA, Sanford NN, Chino F, Gyawali B, Booth CM, Msaouel P, Ludmir EB. Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis. JAMA Oncol. 2025 May. PMID: 40451185.
  13. Chen J, Selokar A, Ho FDV, Jacomina LE, Feliciano EJG, de Luna Uy JMA, Wu JF, Jain U, Jain B, Columbres RC, Treechairusame T, Willmann J, Ting FIL, Iyengar P, Ynoe de Moraes F, Gyawali B, Tangco ED, Flores JA, Shua MLK, Estilo C, Mejia MBA, Lee NY, Dee EC. Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050. The Laryngoscope. 2025 Jul. PMID: 40698853.
  14. Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G, Amaral T, Barriuso J, Calles A, Kiesewetter B, Gomez-Roca C, Gyawali B, Piccart M, Passaro A, Roitberg F, Tarazona N, Trapani D, Curigliano G, Wester R, Zarkavelis G, Zielinski C, de Vries EGE. ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). Ann Oncol. 2025 May. PMID: 40409995.
  15. Wilson BE, Wright K, Sengar M, Sullivan R, Pearsonn SA, Barton MB, Gyawali B, de Vries EGE, Moja L, Pramesh CS, Booth CM. Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource stratified guidelines. J Nat Canc Inst. PMID: 40408185.
  16. Leite LF, de Almeida LFC, da Conceição LD, Macambira Noronha M, Belotto M, Saldanha E, Megid TBC, D’Alpino Peixoto R, Gyawali B. Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis. BMJ Oncol. 2025 May. PMID: 40519225.
  17. Wright K#, Shkabari B#, Booth C, Knopf K, Tregear M, Gyawali B*. Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers: a cross sectional study. eClinicalMedicine. 2025 Apr. PMID: 40235947.
  18. Mittal A, Linnford G, Gyawali B. Inferior control arms in prostate cancer trials: The ARANOTE Trial. 2025 Apr. J Clin Oncol. PMID: 39823549
  19. Cherny NI, Trapani D, Galotti M, Sarr M,  Bricalli G, Roitberg F, Gyawali B, Curigliano G, Blay J-Y, Meier K, Latino NJ, de Vries EGE. ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update. Ann Oncol. 2025 Mar. PMID: 39818519.
  20. Dee EC#, Laversanne M, Bhoo-Pathy N, Ho FDV, Feliciano EJG, Eala MAB, Ting FIL, Ginsburg O, Moraes FY, Gyawali B, Gomez SL, Ng K, Wu JF, Jain U, Jain B, Columbres RC, Matsuda T, Sangrajrang S, Sinuraya ES, Bui TD, Wei W, Won YJ, Foo LL, Ling MCA, Mery L, Soerjomataram I, Bray F. Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis. Lancet Oncol. 2025 Apr. PMID: 40024257.
  21. Eisenhauer EA, Abdihamid O, Booth CM, Cherny N, Fojo AT, Gyawali B, Marini BL, Mohyuddin GR, Pe M, Pond GR, Soto-Perez-de-Celis E, Tannock IF, Trapani D, Tregear M, van der Graaf WTA, Wilson BE. Guidance for discussants of randomized cancer trials at major meetings. Eur J Cancer. 2025 Mar 7;220:115357. PMID: 40117861.
  22. Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock IF. Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. Lancet Oncol. 2025 Feb;26(2):e80-e89. PMID: 39914429.
  23. Gyawali B, Jung EH, Mooney H, Avorn J, Kesselheim AS. Government Funding for the Development of Enzalutamide. JAMA Oncol. 2025 Feb. PMID: 39699929.
  24. Meirson T, Ofer J, Zimhony-Nissim N, Bareket-Samish A, Markel G, Neiman V, Cherny N, Goldstein DA, Gyawali B, Tannock I, Rosenbaum E. Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring. JAMA Netw Open. 2025 Jan 2;8(1):e2455630. PMID: 39841472.
  25. Raptis SG#, Shkabari B#, Banday S#, Gyawali B*. Defining and Measuring Financial Toxicity in Low- and Middle-Income Countries. JCO Oncol Pract. 2025 Jan;21(1):57-68. PMID: 39793549.

2024

  1. Datta SS, Sharma V, Mukherjee A, Agrawal S, Sirohi B, Gyawali B*. What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs. ESMO Open. 2024 Nov;9(11):103976.  Epub 2024 Nov 6. PMID: 39510022
  2. Mittal A#, Kim MS, Dunn S#, Wright K#, Gyawali B*. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward. eClinicalMedicine. 2024 Sep 13. PMID: 39764569
  3. Jain U*, Rahim F., Jain B., Komanduri A., Arkalgud A., Sabet C. J., … & Gyawali B*. (2024). Cancer burden across the South Asian Association for Regional Cooperation in 2022. BMJ Oncology, 3(1). PMID: 39886156
  4. Diprose, K., Wakeham, K., Lewis, P., Lodge, M., Sullivan, R., Sirohi, B., Young, A., Ranasinghe, N., Mutebi, M., Gyawali, B., Cowan, R., & Stanway, S. (2024). UK Cancer Healthcare Professionals Collaborating With Colleagues in Low- and Middle-Income Countries: Mapping the Extent and Nature of Partnerships; Future Implications. Clinical oncology. 2024. PMID: 38909007
  5. Gupta M, Akhtar OS, Bahl B, Meir-Hicks A, Attwood K, Catafamo K, Gyawali B, Torka P. Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncology. BMJ Oncol. 2024 Jul.
  6. Dee EC, Pramesh CS, Booth CM, Rubagumya F, Mutebi M, Feliciano EJG, Eala MAB, Cerri GG, Ginsburg O, Gyawali B, Ynoe de Moraes F. Growing the global cancer care system: success stories from around the world and lessons for the future. J Natl Cancer Inst. 2024 Apr. PMID: 38663853.
  7. Del Paggio JC, Naipaul R, Gavura S, Mercer RE, Koven R, Gyawali B, Wilson BE, Booth CM. Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study. Lancet Oncol. 2024 Apr. PMID: 38547890.
  8. Sanford NN, Gyawali B.* Financial Conflicts of Interest: Payment at the Expense of Patients? JCO Oncol Pract. Mar 2024. PMID: 38498791.
  9. Gyawali, B., Booth C. M., Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients. Lancet Oncol. 2024 Feb.
  10. Hernando-Calvo A, Nguyen P, Bedard PL, Chan KKW, Saleh RR, Weymann D, Yu C, Amir E, Regier DA, Gyawali B, Kain D, Wilson B, Earle CC, Mittmann N, Abdul Razak AR, Isaranuwatchai W, Sabatini P, Spreafico A, Stockley TL, Pugh TJ, Williams C, Siu LL, Hanna TP. Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data. EClinicalMedicine. 2024 Feb 12. PMID: 38380071
  11. Sanford NN, Lievens Y, Aggarwal A, Hanna TP, Dawson LA, White J, Gyawali B, Booth C, de Moraes FY. Common Sense (Radiation) Oncology: Redefining targets in radiotherapy. Radiother Oncol. PMID: 38316192.
  12. Gyawali B*, Poudyal BS, Carson LM, Savage C, Shilpakar R, Berry S. The differential needs and expectations from general practitioners in oncology between high-income countries and low- and-middle-income countries: results from a survey of Canadian and Nepali oncologists. Ecancermedicalscience. 2024 Feb 22. PMID: 38439813
  13. Strohbehn G. W., Gyawali, B.* ‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent. Nat Rev Clin Oncol. 2024 Jan. PMID: 38182900.

2023

  1. Jenei, K., Moraes, F. Y., Gyawali, B.* Globalisation of clinical trials in oncology: A double-edged sword? BMJ Oncol. 2023.
  2. Ranawaka, S., Gunarathna, S., Gunasekera, S., Booth, C. M., Jalink, M., Carson, L. M., Berry, S., Gyawali, B., Seneviratne, S., Wijeratne, D. T. Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income Country With Free Universal Public Healthcare. The Oncologist. 2023. PMID: 37740501.
  3. Booth, C. M., Eisenhauer, E. A., Gyawali, B., Tannock, I. F.   Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs. J Clin Oncol. 2023. PMID: 37733981.
  4. Gyawali B., Kesselheim A.S., Ross J.S., The accelerated approval program for cancer drugs — finding the right balance. N. Engl. J. Med. September 2023. PMID: 37694884
  5. Wright K#, Mittal A#, Gyawali B*. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls. Curr Opin Oncol. 2023. PMID: 37621175.
  6. Frank C, Gyawali B, Booth CM. Common sense cancer care for older adults: Outcomes that matter.  J Am Geriatr Soc. 2023. PMID: 37539843.
  7. West HJ, Akhade A, Gyawali B. Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities. JCO Glob Oncol. 2023 Sep. PMID: 37992268.
  8. Gyawali B*. Problematic crossovers in cancer drug trials. Nat Rev Clin Oncol. 2023. PMID: 37460633.
  9. Booth, C. M., Sengar, M., Goodman, A., Wilson, B., Aggarwal, A., Berry, S., Collingridge, D., Denburg, A., Eisenhauer, E. A., Ginsburg, O., Goldstein, D., Gunasekera, S., Hammad, N., Honda, K., Jackson, C., Karikios, D., Knopf, K., Koven, R., Marini, B. L., … Gyawali, B. Common Sense Oncology: Outcomes that matter. Lancet Oncol. 2023. PMID: 37467768
  10. Jenei K#, Raymakers AJN, Bayle A, Berger-Thürmel K, Cherla A, Honda K, Jackson CCGA, Karikios D, Trapani D, Berry S, Gyawali B. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Lancet Oncol. 2023 Jun. PMID: 37269843.
  11. Kiesewetter B, Dafni U, de Vries EGE, Barriuso J, Curigliano G, González-Calle V, Galotti M, Gyawali B, Huntly BJP, Jäger U, Latino NJ, Malcovati L, Oosting SF, Ossenkoppele G, Piccart M, Raderer M, Scarfò L, Trapani D, Zielinski CC, Wester R, Zygoura P, Macintyre E, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0. Ann Oncol. 2023. PMID: 37343663.
  12. Among the authors of the SISAQOL-IMI Consortium. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol. 2023 Jun. PMID: 37269858.
  13. Rubagumya F, Fundytus A, Keith-Brown S, Hopman WM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Eniu A, Sengar M, Riechelmann RSR, Sullivan R, Booth CM. Allocation of authorship and patient enrollment among global clinical trials in oncology. Cancer. 2023 PMID: 37382190.
  14. Farid-Kapadia M, Barton M, Bider-Canfield Z, Cheema PK, Gyawali B, Nightingale NM, Latifovic L, Conter HJ. Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis. Future Oncol. 2023 Jun. PMID: 37283038.
  15. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience. 2023 Jun 8. PMID: 37396096
  16. Gyawali B, Carson LM, Shuel S, Wilkinson AN, Ostic H, Savage C, Berry S. Training General Practitioners in Oncology: Lessons Learned From a Cross-Sectional Survey of GPOs in Canada. JCO Glob Oncol. 2023 May. PMID: 37141561.
  17. Wright K#, Digby GC, Gyawali B, Jad R, Menard A, Moraes FY, Wijeratne DT. Malignant Superior Vena Cava Syndrome: A Scoping Review. J Thorac Oncol. 2023 May. PMID: 37146753.
  18. Meirson T, Goldstein DA, Gyawali B, Tannock IF. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer. Lancet Oncol. 2023 May 2. PMID: 37146621.
  19. Tannock IF, Goldstein DA, Ofer J, Gyawali B, Meirson T. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer? J Clin Oncol. 2023 PMID: 36961983.
  20. Koczwara B, Chan A, Jefford M, Lam WWT, Taylor C, Wakefield CE, Bhoo-Pathy N, Gyawali B, Harvet G, Lou Y, Pramesh CS, Takahashi M, Ke Y, Chan RJ. Cancer Survivorship in the Indo-Pacific: Priorities for Progress. JCO Glob Oncol. 2023. PMID: 36749908.
  21. Jenei K#, Meyers D, Gyawali B. Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020. JAMA Netw Open. 2023 Jan 3. PMID: 36719684.
  22. Gyawali B, Bowman M, Sharpe I, Jalink M, Srivastava S, Wijeratne DT. A systematic review of eHealth technologies for breast cancer supportive care. Cancer Treat Rev. 2023 Jan. PMID: 36736125.
  23. Jenei K#, Gyawali B. Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting? Healthc Pap. 2023 Jan. PMID: 36692916.

2022

  1. Knopf KB, Gyawali B. Intention to probe into the colonoscopy trial: Is it the procedure or the trial that failed? EClinicalMedicine. 2022 Dec 24. PMID: 36589265.
  2. Oosting SF, Barriuso J, Bottomley A, Galotti M, Gyawali B,…Piccart M, Cherny NI. Methodological and reporting standards for quality of life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. Annals of Oncology. 2022 December 19. PMID: 36549587
  3. Sachdev A#, Sharpe I, Bowman M, Booth CM, Gyawali B*. Objective response rate of placebo in randomized controlled trials of anticancer medicines. EClinicalMedicine. 2022 Nov 24;55:101753. PMID: 36444211. Altmetric score: 97.
  4. Poudyal B, Dulal S, Shilpakar R and Gyawali B* (2022) Highlights from ecancer Choosing Wisely Nepal 2022: critical appraisal skills for evidence-based practice, 24th–25th September 2022, Kathmandu, Nepal ecancer 16 1478. PMID: 36819797
  5. Akhade A, Gyawali B, Sullivan R, Sirohi B (2022). Highlights from the Choosing Wisely 2022 for Resource Limited Settings: Reducing Low Value Cancer Care for Sustainability conference, 17th–18th September, Mumbai, India ecancer 16 1465. PMID: 36819800
  6. Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, Fojo A, Gyawali B, Ilbawi A, Lombe D, Sengar M, Sullivan R, Trapani D, Huttner BD, Moja L. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. Lancet Glob Health. 2022 Dec;10(12):e1860-e1866. PMID: 36183737. Altmetric score: 58
  7. Akhade A, Van Wambeke S and Gyawali B* CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner? ecancer 2022. PMID: 36200010
  8. Rubagumya F, Hopman WM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Zubaryev M, Eniu A, Tsunoda AT, Kutluk T, Aggarwal A, Sullivan R, Booth CM. Participation of Lower and Upper Middle-Income Countries in Clinical Trials Led by High-Income Countries. JAMA Netw Open. 2022 PMID: 35980637
  9. Istasy P, Lee WS, Iansavichene A, Upshur R, Gyawali B, Burkell J, Sadikovic B, Lazo-Langner A, Chin-Yee B. The impact of artificial intelligence on health equity in oncology: A scoping review. J Med Internet Res. 2022. PMID: 36005841.
  10. Gyawali B*, Booth CM. Defining clinically important overall survival thresholds: lessons from quality of life. Nat Rev Clin Oncol. 2022 Jul 27. PMID: 35896739. Altmetric score: 59
  11. Sengar M, Fundytus A, Hopman W, Pramesh CS, Radhakrishnan V, Ganesan P, Mathew A, Lombe D, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Cancer Medicines: What Is Essential and Affordable in India? JCO Glob Oncol. 2022 Jul;8:e2200060. PMID: 35853192.
  12. Strzebonska K, Blukacz M, Wasylewski MT, Polak M, Gyawali B, Waligora M. Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Med. 2022 Jul 8;20(1):219. PMID: 35799149
  13. Denburg AE, Fundytus A, Khan MS, Howard SC, Antillon-Klussmann F, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Glob Oncol. 2022 Jun;8:e2200034. PMID: 35749676.
  14. Wright K#, Meyers DE#, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM. Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians? JCO Oncol Pract. 2022. PMID: 35696634. Altmetric Score: 109
  15. Lythgoe MP, Desai A, Gyawali B, Savage P, Krell J, Warner JL, Khaki AR. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. JAMA Netw Open. 2022 Jun. PMID: 35687337.
  16. Gyawali B*, Thapa N, Savage C, Carson LM, Jalink M, Rawal M, Berry S, Sharma Poudyal B. Training General Practitioners in Oncology: A Needs Assessment Survey From Nepal. JCO Glob Oncol. 2022 May. PMID: 35670697.
  17. Wijeratne DT, Gunasekara S, Booth CM, Berry S, Jalink M, Carson LM, Gyawali B, Promod H, Jayarajah U, Seneviratne S. Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. JCO Glob Oncol. 2022 May. PMID: 35623022.
  18. Samuel JN#, Booth CM, Eisenhauer E, Brundage M, Berry SR, Gyawali B*. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class . JAMA Oncol. 2022 Apr. PMID: 35482347. Altmetric score: 182
  19. Gyawali B* and Booth CM. Cancer treatments should benefit patients: a common-sense revolution in oncology. Nat Med. 2022 Apr;28(4):617-620. PMID: 35440715. Altmetric score: 225
  20. Kartolo A# and Gyawali B*. Should the control arms of randomized trials have an expiry date? Nat Rev Clin Oncol. 2022 Apr 1. PMID: 35365795.
  21. Li X, Beeghly-Fadiel A, Bhavnani SK, Tavana H, Rubinstein SM, Gyawali B, Riaz IB, Fernandes HD, Warner JL. Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Network Open. 2022 Apr 1;5(4):e224361. PMID: 35416993
  22. Wells JC, Fundytus A, Sharma S, Hopman WM, Del Paggio JC, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. Curr Oncol. 2022 Apr 7;29(4):2530-2538. PMID: 35448181
  23. Gyawali B, Eisenhauer E, Tregear M, Booth CM. Progression-free survival: it is time for a new name. Lancet Oncol. 2022 Mar. PMID: 35240080. Altmetric Score: 128
  24. Cherny NI, Dafni U, Pentheroudakis G, Piccart M, Zygoura P, Gyawali B, de Vries EGE. “The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores. ESMO Open. 2022 Mar 10. PMID: 35279525
  25. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer. 2022 Feb. PMID: 35236569.
  26. Van Wambeke S, Vera-Badillo FE, Gyawali B. Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care? J Clin Oncol. 2022 Feb 21. PMID: 35188830. Altmetric Score: 71
  27. Dodkins J, Hopman WM, Wells JC, Lievens Y, Malik RA, Pramesh CS, Gyawali B, Hammad N, Mukherji D, Sullivan PR, Parkes J, Booth CM, Aggarwal A. Is Clinical Research Serving the Needs of the Global Cancer Burden? An analysis of contemporary global radiotherapy randomised controlled trials. Int J Radiat Oncol Biol Phys. 2022 Feb 10. PMID: 35151802.
  28. Akhade A, Sirohi B and Gyawali B*. Global consequences of the US FDA’s accelerated approval of cancer drugs. The Lancet Oncology. 2022 January. PMID: 35114117
  29. Basnet BK, Gautam B, Ranabhat K, Paudel BD, Chapagain Acharya S, Bastola SR, Gyawali B. KRAS Oncogene Mutations in Colorectal Cancer Patients in a Nepalese Tertiary Care Hospital. J Nepal Health Res Counc. 2021 Dec 14;19(3):504-507. PMID: 35140422.
  30. Khan SZ, Arecco L, Villarreal-Garza C, Sirohi B, Ponde NF, Habeeb B, Brandão M, Azim HA Jr, Chowdhury AR, Bozovic-Spasojevic I, Kovalenko I, Odhiambo A, Seid FU, Mutombo AB, Petracci F, Vidra R, Altuna SC, Petrova M, Kourie HR, Ozturk MA, Razeti MG, Lengyel CG, Talibova N, Mariamidze E, Sacardo KP, Duma N, Gyawali B, Trapani D, Tagliamento M, Lambertini M. Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. JCO Glob Oncol. 2022.PMID: 35025688
  31. Gyawali B, Carson L, Berry S and Moraes F. Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs. The Lancet Regional Health – Americas. 2022. Altmetric score: 51
  32. Gyawali B, Griffiths R, Robinson AG, McInnes MDF, Bedard PL, Booth CM. Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines? Can Urol Assoc J. 2022. PMID: 34582333

2021

  1. Wijeratne DT, Booth CM, Seneviratne S, Gyawali B, Jalink M, Soysa M, Abhayaratna S, Promod H, Wijesinghe P, Gunasekera S. Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity? Ecancermedicalscience. 2021. PMID: 34824624
  2. Fu M, Naci H, Booth CM, Gyawali B, et al. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med. 2021. PMID: 34661604
  3. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. Cancer. 2021. PMID: 34614198.
  4. Gyawali B*, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. The BMJ. 2021 PMID: 34497044. Altmetric Score: 305.
    • Covered by STAT News, Medpage Today and several others.
  5. Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021. PMID: 34560006. Altmetric score: 121.
  6. Fundytus A, Wells JC, Sharma S, Hopman WM, Del Paggio JC, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation. Clin Oncol (R Coll Radiol). 2021. PMID: 34479769.
  7. Sharma, S#, Booth, C. M., Eisenhauer, E. A., and Gyawali, B*.  Do Editorialists With Industry-Related Conflicts of Interest Write Unduly Favorable Editorials for Cancer Drugs in Top Journals?. Journal of the NCCN. PMID: 34325401.  Altmetric score: 74
  8. Wijeratne DT, Bowman M, Sharpe I, Srivastava S, Jalink M, Gyawali B*. Text Messaging in Cancer-Supportive Care: A Systematic Review. Cancers (Basel). 2021 Jul 15;13(14):3542. PMID: 34298756.
  9. Gyawali B*, Ross JS, Kesselheim AS. Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway: The Need for Reforms. JAMA Intern Med. 2021 Jul 13. PMID: 34254981. Altmetric score: 482.
  10. Van Wambeke S and Gyawali B. Atezolizumab in Metastatic Triple-Negative Breast Cancer-No Contradiction in the Eyes of a Dispassionate Observer. JAMA Oncol. 2021 Jun 24. PMID: 34165499.
  11. Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, Blukacz M, Gyawali B, Waligora M. Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. Target Oncol. 2021 Jun 10. PMID: 34110559.
  12. Yekedüz E, Trapani D, Xu W, de Vries EG, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Ürün Y. Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors. Int J Cancer. 2021 Jun 14. PMID: 34124786.
  13. Gyawali B*, Darrow JJ, Kesselheim AS. Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling. JAMA Intern Med. 2021 May 17. PMID: 33999146.
  14. Elsolh B, Brar A, Gyawali B, Patel SV. Reviewing the Reviewers: Potential Financial Conflicts of Interest in Editorial Boards of Surgery Journals. Ann Surg. 2021 Jun 2. PMID: 34091509.
  15. Gyawali B*, Jalink M, Effing SMA#, Dalgarno N, Kolomitro K, Thapa N, Sharma Poudyal B, Berry S . Oncology training programmes for general practitioners: a scoping review ecancer 2021. 15 1241. PMID: 34267797
  16. Subedi R, Budukh A, Chapagain S, Gyanwali P, Gyawali B, Khadka K, Thakur C, Dahal U, Dikshit R, Kumar Jha A, Dhimal M. Differences in cancer incidence and pattern between urban and rural Nepal: one-year experience from two population-based cancer registries. ecancer 2021. 15 1229. PMID: 34158833
  17. Thomson S, Witzke N, Gyawali B, Delos Santos S, Udayakumar S, Cardone C, Cheung MC, Chan KKW. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. Eur J Cancer. 2021 Apr 28;150:203-210. PMID: 33932727.
  18. Wijeratne DT, Wright K, Gyawali B*. Risk-Stratifying Treatment Strategies for Febrile Neutropenia-Tools, Tools Everywhere, and Not a Single One That Works? JCO Oncol Pract. 2021 Apr 29. PMID: 33914611.
  19. Gyawali B*, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open. 2021 Apr 19;6(3):100117. PMID: 33887690. Altmetric score: 128
  20. Sharma S#, Wells JC, Hopman WM, Del Paggio JC, Gyawali B, Hammad N, Hay AE, Booth CM. Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. Current Oncology. 2021; 28(2):1518-1527. PMID: 33924380
  21. Luo Z, Gyawali B*, Han S, Shi L, Guan X and Wagner AK. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Seminars in Oncology 2021. PMID: 33875231
  22. Meyers DE, Chisamore TM, McInnes MDF, Gyawali B, Prasad V and Booth CM. Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets. Journal of Cancer Policy 2021. PMID: 35559912
  23. Bhanvadia SK, Psutka SP, Burg ML, de Wite R, Dhillon HM, Gyawali B, Morgans AK, Goldstein DA, Smith AB, Sun M, Penson DF. Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. Eur Urol Oncol. 2021 Apr 2PMID: 33820747.
  24. Subedi R, Dhimal M, Budukh A, Chapagain S, Gyawali P, Gyawali B, Dahal U, Dikshit R, Jha AK. Epidemiologic Pattern of Cancer in Kathmandu Valley, Nepal: Findings of Population-Based Cancer Registry. JCO Glob Oncol. 2021 Mar;7:443-452. PMID: 33788597.
  25. Gyawali B* and Kesselheim A.S. FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer. Nat Rev Clin Oncol 2021. PMID: 33767454. Altmetric score: 115
  26. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B and Booth C. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncol. 2021.  PMID: 33764385. Altmetric score: 174
  27. Meyers DE, Jenei K, Chisamore TM, Gyawali B*. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. JAMA Internal Medicine. 2021. PMID: 33616606. Altmetric score: 132.
  28. Cherla A, Naci H, Kesselheim AS, Gyawali B, Mossialos E. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. JAMA Internal Medicine. 2021. PMID: 33616607. Altmetric score: 67
  29. Delos Santos S, Witzke N, Gyawali B, Arciero VS, Rahmadian AP, Everest L, Cheung MC, Chan KK. Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework. Journal of NCCN. 2021 PMID: 33636693.
  30. Gyawali B*, D’Andrea E, Franklin JM and Kesselheim AS. A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. EClinicalMedicine Published: January 28, 2021  PMID: 33681740
  31. Wells JC, Sharma S, Del Paggio JC, Hopman W, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R and Booth C. An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncol. 2021. PMID: 33507236 Altmetric Score: 132
  32. Merchant SJ, Kong W, Gyawali B, Hanna TP, Chung W, Nanji S, Patel SV, and Booth CM. First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. JCO Oncology Practice. 2021 PMID:  33449833
  33. Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. Chemotherapy Knowledge Base Management in the Era of Precision Oncology. JCO Clin Cancer Inform. 2021 Jan;5:30-35. PMID: 33411619.

2020

  1. Gyawali B* and West J. Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics. Journal of Clinical Oncology. December 04, 2020. PMID: 33275490. Altmetric score: 90
  2. Poudyal B, Gyawali B and Rondelli D. The need for locally generated data in haematology: a real‐world experience of aplastic anaemia in Nepal. British Journal of Haematology. 2020. PMID: 33216359
  3. Gyawali B and Niraula S. Lessons from Adaptive Randomization: Spying the I-SPY2 trial in breast cancer. Journal of NCCN. November,2020. PMID: 33152697
  4. Datta SS, Mukherjee A, Ghose S, Bhattacharya S, Gyawali B. Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic. JCO Glob Oncol. 2020. PMID: 33017180
  5. Poudyal BS, Gyawali B and Rondelli D. Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber ecancer 14 ed104 (2020). PMID: 33082856.
  6. Desai A#, Gyawali B*. Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. ecancer 14 1091 (2020). PMID: 33014133
  7. Poudyal BS, Giri S, Tuladhar S, Neaupane S and Gyawali B*. A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries. The Lancet Haematology. 2020 Volume 7, Issue 9, e638 – e639. PMID: 32853583. Altmetric Score: 53
  8. Merchant SJ, Kong W, Gyawali B, Hanna T, Chung W, Nanji S, Patel SV, Booth CM. Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer. Clin Oncol (R Coll Radiol).  PMID: 32747152
  9. Gyawali B*, Sharma S#, Shilpakar R, Dulal S, Pariyar J, Booth CM, Sharma Poudyal B. Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. JCO Glob Oncol. PMID: 32735488.
  10. Effing S# and Gyawali B*. Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials. Eclinicalmedicine, Published by the Lancet. July 15, 2020 PMID: 32954236
  11. Gyawali B*, Poudyal BS, Eisenhauer EA. Covid-19 Pandemic—An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology? JAMA Oncol. Published online July 02, 2020. doi:10.1001/jamaoncol.2020.2404. PMID: 32614374. Altmetric score: 142
  12. Desai A# and Gyawali B. Endpoints used in phase III randomized controlled trials of treatment options for COVID-19 . Eclinicalmedicine, Published by the Lancet. June 2, 2020.  PMID: 32632415
  13. Desai A#, Kulkarni A, Rajkumar SV and Gyawali B.  Clinical Trial Endpoints in Severe COVID-19. Mayo Clinic Proceedings. PMID: 32753131
  14. Robinson AG, Gyawali B, Evans G. COVID-19 and cancer: do we really know what we think we know? Nat Rev Clin Oncol. 2020;1‐3. doi:10.1038/s41571-020-0394-y PMID: 32424196. Altmetric score: 52. This work has been cited in the WHO policy document, available here.
  15. Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Yataco JAD, Gyawali B et al. Breast cancer early detection: A phased approach to implementation. Cancer. 2020;126 Suppl 10:2379‐2393. doi:10.1002/cncr.32887. PMID: 32348566
  16. Gyawali B*, Hey SP and Kesselheim AS. Evaluating the evidence behind the  surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. Eclinicalmedicine, Published by the Lancet. February, 2020. PMID: 32025656. Altmetric score: 63
  17. Raphael MB, Gyawali B and Booth CM. Real world evidence and regulatory drug approval. Nature Reviews Clinical Oncology 2020. PMID: 32112057.
  18. Gyawali B*, Bouche G, Crisp N. and Andre N. Challenges and opportunities for cancer clinical trials in low- and middle-income countries. Nature Cancer 1, 142–145 (2020). Altmetric score: 135
  19. Sedhom R# and Gyawali B*. When is a suboptimal approach to cancer screening better than none? AMA Journal of Ethics. 2020;22(2):E93-101. PMID: 32048579
  20. Desai A# and Gyawali B*. Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. Eclinicalmedicine, Published by the Lancet. January 31, 2020. PMID: 32300733  Altmetric score: 90
  21. Gyawali B*, D’Andrea E, Franklin JM and Kesselheim AS. Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. Journal of NCCN. 2020 January. PMID: 31910385. Altmetric score: 59

2019

  1. Gupta A, Wang P, Ali SA, Rajkumar SV, Gyawali B, Overton HN, Makary MA. Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma. JAMA Oncology. 2019 Dec. PMID: 31830210. Altmetric score:81
  2. Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R, Traversa G, Perrone F, Martini N, Gyawali B, Addis A. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. BMJ Open. 2019 Dec. PMID:  31826897
  3. Gyawali B*, Sharma S# and Booth CM. Is the number of cancer drug approvals a surrogate for regulatory success? Journal of Cancer Policy. 2019. Altmetric score: 51
  4. Hey SP, Gyawali B, D’Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS.  A Systematic Review and Meta-analysis of Bevacizumab in First-line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises. J Natl Cancer Inst. 2019 Oct. PMID: 31651981
  5. Naci H, Davis C, Savović J, Higgins JPT, Sterne JAC, Gyawali B, Romo-Sandoval X, Handley N, Booth CM. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ. 2019 Sep. PMID: 31533922. Altmetric Score: 396
  6. Gyawali B, Bouche G, Pantziarka P, Kesselheim AS, Sarpatwari A.  Lung Cancer Survival Gains: Contributions of Academia and Industry. J Law Med Ethics. 2019 Sep. PMID: 31560624
  7. Hey SP, D’Andrea E, Jung EH#, Tessema F#, Luo J, Gyawali B and Kesselheim AS.  Challenges and opportunities for biomarker validation. J Law Med Ethics. 2019 Sep. PMID: 31560620
  8. Gyawali B*, Tessema FA, Jung EH, Kesselheim AS. Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis. JAMA Netw Open. Published online August 30, 20192(8):e199570. PMID: 31469391 Altmetric score: 104
  9. Gyawali B*, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine. 2019. PMID: 31135808. Altmetric Score: 72
  10. Addeo A, Weiss GW and Gyawali B. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis. JAMA Network Open 2019. PMID: 31074821 Altmetric Score: 85
  11. Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, and Muro K. Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer. Journal of Global Oncology 2019. PMID: 31070981
  12. Passaro A, Spitaleri G,  Gyawali B and de Marinis F. Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. Journal of Clinical Oncology. 2019. PMID: 30995172
  13. Parikh RB, Galsky MD, Gyawali B, Riaz F, Kauffman T, Cohen AB, Adamson BJS, Gross CP, Meropol NJ and Mamtani R. Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice. The Oncologist. 2019. PMID:  30944183.
  14. Gyawali B* and Kesselheim AS. US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent? JAMA Oncology. 2019. PMID: 30920591 Altmetric score: 127
  15. Gyawali B and Prasad V. Making adjuvant therapy decisions with uncertain data. Annals of Oncology. 2019. PMID: 30715160. Altmetric score: 80
  16. Mamtani, R. , Wang, X. V., Gyawali, B. , DiPaola, R. S., Epperson, C. N., Haas, N. B. and Dutcher, J. P.  Association between age and sex and mortality after adjuvant therapy for renal cancer. Cancer. 2019. PMID: 30620389

2018

  1. Gyawali B*. Meta-analyses and RCTs in oncology: what is the right balance? The Lancet Oncology. December 2018. PMID: Altmetric score:93
  2. Gyawali B*, Shimokata T, Honda K and Ando Y. Reporting harms more transparently in trials of cancer drugs. The BMJ. 2018 Nov 1;363:k4383. PMID: 30385466. Altmetric score: 365
  3. Hwang TJ and Gyawali B*. Association between progression-free survival and patients’ quality of life in cancer clinical trials. International Journal of Cancer 2018. PMID: 30374970. Altmetric score: 78
  4. Gyawali B* and Kesselheim AS. The Promise of ESCAT: A New System for Evaluating Cancer Drug-Target Combination. Nature Reviews Clinical Oncology 2018. PMID: 30317250
  5. Ido S, Gyawali B and Goldstein D. Duration of Adjuvant Immunotherapy – Biologic, Clinical and Economic Considerations. Medical Oncology December 2018, 35:160. PMID: 30374666
  6. Pantziarka P, Verbaanderd C, Sukhatme V, Capistrano R, Crispino S, Gyawali B, Rooman I, Van Nuffel A, Meheus L, Sukhatme VP and Bouche G. ReDO_DB: the repurposing drugs in oncology database. Ecancermedicalscience. Published online Dec 6, 2018. PMID: 30679953
  7. Weir I.R , Marshall G.D., Schneider JI, Sherer JA, Lord EM, Gyawali B, Pasasche-Orlow MK, Benjamin EJ and  Trinquart L.  Interpretation of Time-to-event Outcomes in Randomized Trials: an online randomized experiment. Annals of Oncology Published online 18 October 2018. PMID: 30335127.
    • With editorial by Drs. Saad ED and Tannock IF.
  8. Gyawali B and Kesselheim AS. Reinforcing the social compromise of accelerated approval. Nature Reviews Clinical Oncology 2018. PMID: 29970919 Altmetric score: 64
  9. Gyawali B*. Does global oncology need artificial intelligence? The Lancet Oncology. May 2018. PMID: 29726374 Altmetric score: 54
  10. Niraula S and Gyawali B. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2018. PMID: 30238273
  11. Gyawali B*, Kesselheim AS and d’Andrea Elvira. Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality? International Journal of Cancer 2018. PMID: 30152520
  12. Gyawali B* and Addeo A. Negative Phase 3 Randomized Controlled Trials: Why cancer drugs fail the last barrier? International Journal of Cancer. 2018 May. PMID: 29744864. Altmetric score: 63
  13. Gyawali B*, Hey SP and Kesselheim AS. Correlation and differences in effect sizes between progression-free survival and overall survival with PD-1 inhibitors. JAMA Network Open. June 22,2018. Altmetric score: 57
    • Poster presentation at ESMO 2017. Travel grants awarded.
  14. Honda K, Gyawali B, Ando M, et al. A prospective survey of comprehensive Score for financial Toxicity in Japanese cancer patients: report on a pilot study. ecancermedicalscience 12 847. PMID: 30079109
    • Oral presentation at JSMO 2018 Annual Meeting. The first author won young investigator award for this research.
  15. Gyawali B* and Niraula S. Cancer treatment in the last 6 months of life: when inaction can outperform action. Ecancermedicalscience. 2018 April. PMID: 29743946. Altmetric score: 259
  16. Gyawali B* and Goldstein D. The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture? JAMA Oncology. May 2018. PMID: 29522146. Altmetric score: 105
  17. Gyawali B*, Sullivan R and Booth CM. Cancer groundshot: going global before going to the moon. The Lancet Oncology. 2018 March. PMID: 29508746. Altmetric score: 89
  18. Hwang TJ, Kesselheim AS and Gyawali B*. Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007-2016. JNCI Cancer Spectrum. 1 June,2018. PMID: 31360849
  19. Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS and Darrow JJ. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer Medicines. Journal of Clinical Oncology. 2018 Apr 24. PMID: 29688832
    • With editorial by Nicole Kuderer and Gary Lyman.
  20. Dhakal B, Szabo A, Chhabra S,Hamadani M, D’Souza A, Usmani S, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F and Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncology 2018. PMID: 29302684 
  21. Bhatt VR, Chen B, Gyawali B and Lee SJ. Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. Bone Marrow Transplant. 2018 March. PMID: 29588500
  22. Gyawali B*, Patziarka P, Crispino S and Bouche G. Does the oncology community have a rejection bias when it comes to repurposed drugs? Ecancer 2018, ed76. Published 16 Jan, 2018. PMID: 29456622

2017

  1. Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, Gyawali B, Kubo Y, Ando M, Kondo M, Yamada K, Hasegawa Y and Ando Y. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. The Oncologist 2017.  PMID: 29038236
  2. Gyawali B and Niraula S. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials. Cancer Treatment Reviews 2017.  PMID: 28863313
  3. Fernandes R, Mazzarello S, Stober C, Ibrahim MFK, Dudani S, Perdrizet K, Majeed H, Vandermeer L, Shorr R, Hutton B, Fergusson D, Gyawali B, and Clemons M. Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. Journal of Global Oncology. PMID: 30241156
  4. Gyawali B*. The OlympiAD trial: Who Won the Gold? ecancer 2017, 11:ed75. Published December 6, 2017. PMID : 29290761
  5. Gyawali B, Parsad S, Feinberg B and Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precision Oncology 2017:1, 1-5. Altmetric Score: 100
  6. Gyawali B (2017).* Low-value practices in oncology contributing to financial toxicity. Ecancermedicalscience. 11: 727  (PMID: 28386297). Altmetric score: 118.
  7. Gyawali B and Prasad V. Health policy: Me-too drugs with limited benefits – the tale of regorafenib for HCC. Nature Reviews Clinical Oncology. (PMID: 28719584) . Altmetric score:83.
  8. Gyawali B and Prasad V. Pemetrexed in Nonsquamous Non–Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis JAMA Oncology. (PMID: 28750129) . Altmetric score:105.
  9. Gyawali B* and Ando Y. Adjuvant Sunitinib for high-risk resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials. Annals of Oncology. (2017) 28 (4): 898-899. (PMID: 27993814).
  10. Gyawali Bishal.* The Imprecise Pursuit of Precision Medicine: Are biomarkers to blame? Journal of the NCCN. 2017 Jul;15(7):859-862. doi: 10.6004/jnccn/2017.0126 (PMID: 28687572). Altmetric score: 84
  11. Adhikari J, Gyawali B, Sharma P and Bhatta VR. Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant. Future Oncology. 2017 Apr;13(10):935-944. doi: 10.2217/fon-2016-0443. (PMID: 27935324)
  12. Gyawali B* and Sullivan R. Economics of Cancer Medicines: for whose benefit? The New Bioethics. Vol. 23 , Iss. 1,2017 (PMID: 28517989) . Altmetric score: 76.
  13. Gyawali B and Prasad V. Combining drugs and extending treatment-a PFS endpoint is not sufficient. Nature Reviews Clinical Oncology. (PMID: 28534528) . Altmetric score:75.
  14. Gyawali B*, Shimokata T, Ando M, Honda K and Ando Y. Risk of Serious Adverse Events and Fatal Adverse Events with Sorafenib use in Patients with Solid Cancer: A meta-analysis of phase 3 Randomized Controlled Trials. Annals of Oncology. (2017) 28 (2): 246-253. (PMID: 27771613).
  15. Gyawali B* and Iddawela M. Bevacizumab in advanced cervical cancer: issues and challenges for low- and middle- income countries. Journal of Global Oncology. 3, no. 2 (April 2017) 93-97. (PMID: 28717748)
  16. Gyawali B and Prasad V. Drugs that lack single-agent activity: are they worth pursuing in combination? Nature Reviews Clinical Oncology. 2017 Apr;14(4):193-194. (PMID: 28266519). Altmetric score: 93

2016

  1. Sharma-Poudyal B, Sapkota B, Shrestha G, Thapalia S, Gyawali B and Tuladhar S. Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura. Journal of Nepal Medical Association, v. 55, n. 203, p. 16-21, sep. 2016. (PMID: 27935917)
  2. Khoja L and Gyawali B*. Adoptive Cell Therapy and modulation of the tumour microenvironment: New Insights from ASCO 2016. Ecancermedicalscience (PMID: 27610200).
  3. Sharma-Poudyal B, Shrestha G. S, Tuladhar S, Gyawali B, Sedain G, Battajo R, Maskey P, Paudyal S, Regmi S, R.C. D.R and Kouides P. Use of donated clotting factors for surgeries on hemophilic patients in a resource constrained country: a kind donor, good outcome, change of practice and future directions. Haemophilia (2016). 22: e453–e455. doi:10.1111/hae.13017 (PMID: 27353411)
  4. Gyawali B* and Prasad V. Negative trials in ovarian cancer: is there such a thing as too-much optimism? Ecancermedicalscience. (PMID: 27594913).
  5. Gyawali B*, Shimokata T, Honda K, Kondoh C, Hayashi N, Yoshino Y, Sassa N, Nakano Y, Gotoh M and Ando Y. Muscle wasting associated with the long term use of mTOR inhibitors. Molecular and clinical Oncology, 5, 641-646. (PMID: 27900103).
  6. Sharma-Poudyal B, Tuladhar S and Gyawali B*. TKI-induced Pure Red Cell Aplasia: First Case Report of pure red cell aplasia with both imatinib and nilotinib. ESMO-Open May 2016, 1 (3) e000058; (PMID: 27843612)
  7. Gyawali B*, Shimokata T, Honda K, Tsukuura T and Ando Y. Should low-income countries spend on breast-cancer screening? Cancer Causes and Control (2016) 27:1341. (PMID: 27680017)
  8. Gyawali B and Prasad V. Same data; different interpretations. Journal of Clinical Oncology. 34, 31: 3729-3732., 2016, (PMID: 27573659). Altmetric score: 112
    • 19th most read article in ASCO Journals (JCO, JOP, JGO) (as of Dec.21, 2016)
  9. Gyawali B*, Poudyal B and Iddawela M. Cheaper options in the prevention of Chemotherapy Induced Nausea and Vomiting. Journal of Global Oncology 2016;2:3. 145-153. PMID: 28717694
    • Included in the Best of JGO 2016 collection.
  10. Gyawali B*, Shimokata T, Honda K and Ando Y. Chemotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Treatment Reviews. 44:10-6. (PMID: 26924194)
  11. Gyawali B*. Me, too. Comments and Controversies. Journal of Global Oncology 2, no. 3 (June 2016) 99-104. PMID: 28717688
  12. Sharma P. B, Gyawali B*, Sapkota B, Tuladhar S, Shrestha G. S, and Rondelli D.  Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries. Leukemia & lymphoma (2016) 2: 57, 474-476 (PMID: 26014274)
  13. Gyawali B*, Koomulli-Parambil S, Iddawela M. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. Critical Reviews in Oncology/Hematology.  2016;102. (PMID : 27157868)

2015

  1. Hayashi N, Ando Y, Gyawali B, Shimokata T, Maeda O, Fukaya M, Goto H, Nagino M and Kodera Y. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncology Reports 35, 1727-1731. (PMID: 26648321).
  2. Sharma Poudyal B, Gyawali B*, Tuladhar S, Kapali K and Shrestha G. S. (2015), Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal. British Journal of Haematology. doi: 10.1111/bjh.13645 (PMID : 26303869)
  3. Tsukuura H, Ando Y, Gyawali B, Matsumoto M, Sugishita M, Honda K, Urakawa H, Maeda O and Hasegawa Y. Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians. Journal of Palliative Medicine 2015;18:977-80.(PMID: 26509390)
  4. Morita S, Hiramatsu M, Sugishita M, Gyawali B, Shibata T, Shimokata T, Urakawa H, Mitsuma A, Moritani S, Kubota T, Ichihara S and Ando Y. Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report. Oncology Letters 10.2 (2015): 972-974. (PMID: 26622607)
  5. Gyawali B*, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y. Opioid-induced constipation. Scandinavian Journal of Gastroenterology 2015;50:1331-8. (PMID:26061717)